Literature DB >> 16334503

Euthyroid Graves' ophthalmopathy with negative autoantibodies.

Mehtap Cakir1.   

Abstract

Graves' disease is an autoimmune-based hyperthyroidism in which a number of different antibodies directed against thyroid tissue plays a role. Graves' ophthalmopathy is thought to be a consequence of this autoimmune basis and occurs in some patients with Graves' disease. On occasional cases, the disease may present only with ophthalmopathy without hyperthyroidism. A 32-year-old woman with euthyroid Graves' ophthalmopathy and negative thyroid autoantibodies, including TSH receptor antibody, is presented here.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16334503      PMCID: PMC2594903     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  15 in total

1.  The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease.

Authors:  W B Kim; H K Chung; Y J Park; D J Park; K Tahara; L D Kohn; B Y Cho
Journal:  Thyroid       Date:  2000-07       Impact factor: 6.568

2.  Association of the HLA-DRB1*0301 and HLA-DQA1*0501 alleles with Graves' disease in a population representing the gene contribution from several ethnic backgrounds.

Authors:  L M Maciel; S S Rodrigues; R S Dibbern; P A Navarro; E A Donadi
Journal:  Thyroid       Date:  2001-01       Impact factor: 6.568

Review 3.  Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.

Authors:  Bellur S Prabhakar; Rebecca S Bahn; Terry J Smith
Journal:  Endocr Rev       Date:  2003-12       Impact factor: 19.871

4.  The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy.

Authors:  D H Khoo; S C Ho; L L Seah; K S Fong; E S Tai; S P Chee; P H Eng; S E Aw; A C Fok
Journal:  Thyroid       Date:  1999-12       Impact factor: 6.568

5.  Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.

Authors:  D H Khoo; P H Eng; S C Ho; E S Tai; N G Morgenthaler; L L Seah; K S Fong; S P Chee; C T Choo; S E Aw
Journal:  Thyroid       Date:  2000-12       Impact factor: 6.568

6.  Racial differences in normal values of proptosis.

Authors:  E de Juan; D P Hurley; J D Sapira
Journal:  Arch Intern Med       Date:  1980-09

7.  Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.

Authors:  J Y Noh; N Hamada; Y Inoue; Y Abe; K Ito; K Ito
Journal:  Thyroid       Date:  2000-09       Impact factor: 6.568

8.  Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease.

Authors:  S Y Goh; S C Ho; L L Seah; K S Fong; D H C Khoo
Journal:  Clin Endocrinol (Oxf)       Date:  2004-05       Impact factor: 3.478

9.  Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease.

Authors:  S Costagliola; N G Morgenthaler; R Hoermann; K Badenhoop; J Struck; D Freitag; S Poertl; W Weglöhner; J M Hollidt; B Quadbeck; J E Dumont; P M Schumm-Draeger; A Bergmann; K Mann; G Vassart; K H Usadel
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

10.  Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.

Authors:  W B Kim; H K Chung; Y J Park; D J Park; H K Lee; B Y Cho
Journal:  Korean J Intern Med       Date:  2001-09       Impact factor: 2.884

View more
  7 in total

1.  Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.

Authors:  B Gopinath; R Musselman; N Beard; S El-Kaissi; J Tani; C-L Adams; J R Wall
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients.

Authors:  S Y Jang; S Y Lee; E J Lee; J S Yoon
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

3.  Thyroid antibody-negative euthyroid Graves' ophthalmopathy.

Authors:  Arshiya Tabasum; Ishrat Khan; Peter Taylor; Gautam Das; Onyebuchi E Okosieme
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-06-02

4.  Thyroid-associated orbitopathy in patients with thyroid carcinoma: A case report of 5 cases.

Authors:  Peng Yu; Siyue Liu; Xinrong Zhou; Teng Huang; Yaling Li; Hong Wang; Gang Yuan
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

5.  Clinical course of thyroid function and thyroid associated-ophthalmopathy in patients with euthyroid Graves' disease.

Authors:  Nami Suzuki; Jaeduk Yoshimura Noh; Toshiaki Kameda; Ai Yoshihara; Hidemi Ohye; Miho Suzuki; Masako Matsumoto; Yo Kunii; Kenji Iwaku; Natsuko Watanabe; Koji Mukasa; Ai Kozaki; Toshu Inoue; Kiminori Sugino; Koichi Ito
Journal:  Clin Ophthalmol       Date:  2018-04-19

6.  A Case of Euthyroid Graves' Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody.

Authors:  Asami Hotta; Tomohiro Tanaka; Haruka Kato; Shota Kakoi; Yuki Shimizu; Chie Hasegawa; Akiko Hayakawa; Satoshi Yasuda; Kento Ogawa; Shunsuke Ito; Hideomi Ohguchi; Takashi Yagi; Hiroyuki Koyama; Mihoko Kawamura; Kazuhiko Sugitani; Yuichiro Ogura; Takashi Joh; Kenro Imaeda
Journal:  Case Rep Endocrinol       Date:  2018-06-13

7.  Exophthalmos and multinodular goitre, an unusual combination.

Authors:  Kingsley Okolie; Daniel Chen; Raf Ghabrial; Robert Schmidli
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-05-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.